Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico

Plain-language summary

This study investigates how often inherited (germline) genetic mutations associated with hereditary pancreatic cancer occur in patients diagnosed with pancreatic cancer in Mexico, using the Invitae Multi-Cancer Panel ® test. It enrolled patients aged 18 and over with histologically confirmed pancreatic adenocarcinoma diagnosed within the previous 6 months. This is a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Intervention

Invitae Multi-Cancer Panel ®

Start date

9/9/2020

Estimated completion

6/30/2022

Countries

Mexico

Related genes

Locations

• Mexico City, Mexico

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Female and male participants ≥ 18 years of age.
* Diagnosed within the previous 6 months with histologically confirmed pancreatic adenocarcinoma stage I to IV.
* Participant provides written informed consent for the study.
* Participant must agree to sample collection and genetic testing using the Invitae Multi-Cancer Panel ®.

Exclusion Criteria:

* Diagnosed with pancreatic adenocarcinoma more than 6 months before presenting to the clinical site.
* Diagnosed with intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, pancreatic neuroendocrine tumors.